CEP55 overexpression is validated to facilitate the malignant phenotypes of cancer cells in diverse tumors, including hepatocellular carcinoma, esophageal squamous cell carcinoma, renal carcinoma, glioma, breast cancer and NSCLC [34–41]. Here, CEP55 is linked to glioma.